Novo Nordisk Slips On Analyst Warning Of Weaker Wegovy Sales
In this article:
Novo Nordisk stock fell after a JPMorgan analyst said sales of its blockbuster weight-loss drug may be weaker-than-expected.
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
Novo Nordisk stock fell after a JPMorgan analyst said sales of its blockbuster weight-loss drug may be weaker-than-expected.